employed protein splicing technology to generate an IgG-like bispecific antibody (CD3 × EpCAM BsAb) capable of binding CD3 on T cells and EpCAM on tumor cells, enabling efficient T-cell redirection and activation. The gene discussed is EPCAM; the disease is neoplasm.